These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 9200764)
1. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Suzuki A; Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Kaneko S; Inoue Y; Shibata M; Ikeda K Ther Drug Monit; 1997 Jun; 19(3):261-4. PubMed ID: 9200764 [TBL] [Abstract][Full Text] [Related]
2. No interaction between desipramine and bromperidol. Suzuki A; Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Kaneko S; Inoue Y Prog Neuropsychopharmacol Biol Psychiatry; 1996 Oct; 20(7):1265-71. PubMed ID: 8938825 [TBL] [Abstract][Full Text] [Related]
3. Interaction between carbamazepine and bromperidol. Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Furukori H; Kaneko S; Inoue Y Eur J Clin Pharmacol; 1997; 52(3):219-22. PubMed ID: 9218929 [TBL] [Abstract][Full Text] [Related]
4. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol. Yasui N; Otani K; Kondo T; Suzuki A; Furukori H; Kaneko S; Inoue Y Prog Neuropsychopharmacol Biol Psychiatry; 1998 Apr; 22(3):485-92. PubMed ID: 9612845 [TBL] [Abstract][Full Text] [Related]
5. Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite. Suzuki A; Otani K; Mihara K; Yasui N; Kondo T; Tokinaga N; Furukori H; Kaneko S; Inoue Y; Hayashi K Psychopharmacology (Berl); 1998 Feb; 135(4):333-7. PubMed ID: 9539256 [TBL] [Abstract][Full Text] [Related]
6. Prolactin response to bromperidol treatment in schizophrenic patients. Yasui N; Kondo T; Otani K; Ishida M; Mihara K; Suzuki A; Kaneko S; Inoue Y Pharmacol Toxicol; 1998 Mar; 82(3):153-6. PubMed ID: 9553995 [TBL] [Abstract][Full Text] [Related]
7. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S; Otani K Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):575-8. PubMed ID: 11999910 [TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy, extrapyramidal symptoms and serum levels: influence of administration schedules and concomitant drugs on serum bromperidol concentrations. Fujii Y; Tateyama M; Kamisada M; Tanoue A; Takamiya M; Nakajima S; Itoh H Folia Psychiatr Neurol Jpn; 1984; 38(2):121-36. PubMed ID: 6152433 [TBL] [Abstract][Full Text] [Related]
9. No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite. Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Kaneko S; Inoue Y; Shibata M; Ikeda K Ther Drug Monit; 1997 Apr; 19(2):165-8. PubMed ID: 9108644 [TBL] [Abstract][Full Text] [Related]
10. Interactions between neuroleptics and CYP2C6 in rat liver--in vitro and ex vivo study. Haduch A; Ogórka T; Boksa J; Daniel WA Pharmacol Rep; 2005; 57(6):872-7. PubMed ID: 16382211 [TBL] [Abstract][Full Text] [Related]
11. No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol. Mihara K; Otani K; Yasui N; Ishida M; Kondo T; Suzuki A; Furukori H; Nagashima U; Kaneko S; Inoue Y Ther Drug Monit; 1999 Jun; 21(3):297-300. PubMed ID: 10365640 [TBL] [Abstract][Full Text] [Related]
12. [Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol]. Furukori H Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):9-14. PubMed ID: 9592806 [TBL] [Abstract][Full Text] [Related]
14. Poor reliability of therapeutic drug monitoring data for haloperidol and bromperidol using enzyme immunoassay. Yasui-Furukori N; Furukori H; Saito M; Inoue Y; Kaneko S; Tateishi T Ther Drug Monit; 2003 Dec; 25(6):709-14. PubMed ID: 14639057 [TBL] [Abstract][Full Text] [Related]
15. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. Furukori H; Kondo T; Yasui N; Otani K; Tokinaga N; Nagashima U; Kaneko S; Inoue Y Psychopharmacology (Berl); 1999 Jul; 145(2):189-92. PubMed ID: 10463320 [TBL] [Abstract][Full Text] [Related]
16. Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. Bagli M; Höflich G; Rao ML; Langer M; Baumann P; Kolbinger M; Barlage U; Kasper S; Möller HJ Int J Clin Pharmacol Ther; 1995 Dec; 33(12):646-52. PubMed ID: 8963481 [TBL] [Abstract][Full Text] [Related]
17. Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol. Yasui-Furukori N; Saito M; Furukori H; Inoue Y; Someya T; Kaneko S; Tateishi T Ther Drug Monit; 2004 Jun; 26(3):336-41. PubMed ID: 15167638 [TBL] [Abstract][Full Text] [Related]
18. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Tateishi T; Watanabe M; Kumai T; Tanaka M; Moriya H; Yamaguchi S; Satoh T; Kobayashi S Life Sci; 2000 Nov; 67(24):2913-20. PubMed ID: 11133003 [TBL] [Abstract][Full Text] [Related]
19. Bromperidol decanoate (depot) for schizophrenia. Purgato M; Adams CE Cochrane Database Syst Rev; 2011 Sep; (9):CD001719. PubMed ID: 21901678 [TBL] [Abstract][Full Text] [Related]
20. Depot bromperidol decanoate for schizophrenia. Wong D; Adams CE; David A; Quraishi SN Cochrane Database Syst Rev; 2004; (3):CD001719. PubMed ID: 15266450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]